The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Pertussis Toxin

Pertussis Toxin

Pertussis toxin is a crucial exotoxin produced by the bacterium Bordetella pertusssis, the causative agent of the respiratory illness whooping cough.
This multifunctional protein plays a central role in the pathogenesis of pertussis, exhibiting a range of biological activities that contribute to the severity of the disease.
Pertussis toxin has been extensively studied for its potential applications in vaccine development, as well as its use as a research tool to elucidate cellular signaling pathways.
Optimizing the use of pertussis toxin in your research can be facilitated by PubCompare.ai, a platform that leverages advanced AI to identify the most effective products and methodologies from the available literature, pre-prints, and patents.
This can enhance the reproducibility and accuracy of your pertussis toxin-related studies.

Most cited protocols related to «Pertussis Toxin»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2008
Blood CD4 Positive T Lymphocytes Cells HIV Infections Infection jasplakinolide latrunculin A Marshes Peptides Pertussis Toxin Staurosporine
Re-stimulated cells were collected and extensively washed with PBS. 3–5 × 106 cytokine producing cells were injected i.v. into C57Bl/6 recipients. In some of the experiments recipient mice were injected i.p. with 150 ng pertussis toxin (PT) (List Biological Laboratories) on day 0 and day 2 after T cell transfer. Animals were monitored daily for development of EAE according to the following criteria: 0, no disease; 1, decreased tail tone; 2, hind limb weakness or partial paralysis; 3, complete hind limb paralysis; 4, front and hind limb paralysis; 5, moribund state. Mice were sacrificed for histopathological analysis at day 40 after transfer.
Publication 2009
Animals Asthenia Biopharmaceuticals Cells Cytokine Hindlimb Mus Paresis Pertussis Toxin T-Lymphocyte Tail

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Adoptive Transfer alum, potassium B-Lymphocytes Cells Cone-Rod Dystrophy 2 Escherichia coli Flow Cytometry FTY-720 Germinal Center Glutathione Institutional Animal Care and Use Committees Light Lycopersicon esculentum Lymphocyte Macrophage Medulla Oblongata Motility, Cell Mus NP 10 Pertussis Toxin Phycoerythrin PRDM1 protein, human Spleen SPN protein, human T-Lymphocyte Tissue Donors Transgenes Vaccination
T. gondii infection was established by intraperitoneal injection of ovalbumin-expressing Prugnauid strain (PruOVA) tachyzoites. Real time PCR was performed for chemokine receptor expression and T. gondii DNA quantification. Brain mononuclear cells were stained with fluorescently conjugated antibodies for flow cytometric analysis. OT-I cells were activated in vitro and transferred to recipient mice. Mice were treated with four doses of 100 μg of anti-CXCL10 for week-long depletion studies or 300 μg 18 hours prior to imaging studies. Pertussis toxin was administered at 400 μg/kg six hours before imaging. For MP microscopy, explant brain was imaged using a Leica SP5 2-photon microscopy system. Cell tracking was performed using Volocity software. In order to create displacement histograms without binning artifacts30 (link) (Supplementary Tables 2-3), a constant number of displacements were placed in each bin. Various statistical methods were applied to test the validity of the generalized Lévy walk model (see Fig. 3, Supplementary Figs. 3, 5, 7, 8, 10, Supplementary Table 1, and Supplementary Discussion). Brownian dynamics-like simulations were performed to simulate the general behavior and searching capability of Gaussian (“random”) and Lévy walkers (see Supplementary Discussion). N searchers were placed in a spherical volume of radius b, and they moved stochastically until finding the target of radius a, which was stationary at the center of the sphere. During random walks, searchers moved 6DΔt = 0.1μm in the x-, y-, or z-direction each time step; here D is the motility coefficient and Δt is the time step. In Lévy walk simulations, a direction for a run was chosen at random, and run lengths were drawn from a Lévy distribution with exponent μrun=2.15. Searchers moved a distance vΔt each time step until the run was completed. After each run, the walker paused for a time drawn from Lévy distribution with μpause=1.7.
Publication 2012
Antibodies Brain Cells Chemokine Receptor Displacement, Psychology Figs Flow Cytometry Infection Injections, Intraperitoneal Microscopy Motility, Cell Mus Ovalbumin Pertussis Toxin Radius Real-Time Polymerase Chain Reaction Strains T-DNA Walkers
Mice were examined routinely for the development of spontaneous disease. Three different protocols were used to induce disease in transgenic and nontransgenic mice. Mice were immunized with 100 μg MOG 35–55 emulsified in CFA (CFA supplemented with 400 μg/ml Mycobacterium tuberculosis) and injected intravenously on days 0 and 2 with 150 ng pertussis toxin. In a second protocol, mice received only injections of pertussis toxin. In a third protocol, mice were immunized with either 10 or 100 μg MOG 35–55 peptide emulsified in CFA without any pertussis toxin. Clinical assessment of EAE was performed daily according to the following criteria: 0, no disease; 1, decreased tail tone; 2, hind limb weakness or partial paralysis; 3, complete hind limb paralysis; 4, front and hind limb paralysis; 5, moribund state.
Mice developing spontaneous optic neuritis presented eyelid redness and swelling associated with tearing. In some cases these signs evolved to a partial or complete atrophy of the eye.
Publication 2003
Animals, Transgenic Asthenia Developmental Disabilities Erythema Eyelids Hindlimb Mice, Laboratory Mycobacterium tuberculosis Optic Atrophy Optic Neuritis Paresis Peptides Pertussis Toxin Tail

Most recents protocols related to «Pertussis Toxin»

Example 6

This example provides a showing of an effect of disclosed anti-PD-L1 antibodies on the progression of disease in a murine model of multiple sclerosis (MS). Anti-PD-L1 antibodies were assayed for their ability to modulate the course of disease in mice induced to develop experimental autoimmune encephalitis (EAE) as a model of MS. Disease was induced in C57Bl/6 mice following injection of myelin oligodendrocyte glycoprotein (MOG) peptide and pertussis toxin. Once symptoms of disease developed, the mice were treated every second day with an intraperitoneal injection of anti-PD-L1 antibody (0.1 mg). The results shown in FIG. 6 provide that both anti-PD-L1 antibodies H6 and H10 impacted the course of disease development with H6 greatly reducing disease severity.

Full text: Click here
Patent 2024
Anti-Antibodies Antibodies, Anti-Idiotypic Antigens Binding Proteins CD274 protein, human Disease Progression Hashimoto's encephalitis Injections, Intraperitoneal Mice, Inbred C57BL Multiple Sclerosis Mus Oligodendrocyte-Myelin Glycoprotein Peptides Pertussis Toxin
Mice were induced with active EAE six to ten weeks post Tamoxifen treatment (after replenishment of IGF-1R+ blood monocytes by natural turnover), as previously described [44 (link)]. Briefly, at day 0, mice were immunized with an emulsion of 200 μg MOG peptide (MOG35-55, Genscript, USA) and complete Freund´s adjuvant (Santa Cruz Biotechnology) containing Mycobacterium tuberculosis (Difco) (100 μl/mouse subcutaneously, in the left and right flank and at the tail base). Furthermore, 400 ng pertussis toxin (List Biological Laboratories, Campbell, CA, USA) diluted in sterile DPBS was administered intraperitoneally at day 0 and day 2.
The weight of the mice was recorded daily and the clinical disease course was assessed using a 0–3 score scale as described in [93 (link)]. Mice displaying a 3–5% weight loss but no other motor impairments received a score of 0 (weight-loss stage), animals showing a limp tail were scored as 0.5 (day of clinical onset), mice displaying a partial weakening of hind limbs received a score of 1 and animals presenting hind limb paraparesis/paraplegia were scored with 2 (symptomatic disease peak). Mice displaying hindlimb paralysis and forelimbs paraparesis were scored with 3 and met termination criteria. For each EAE group, the disease incidence as well as the area under the curve was calculated to assess the clinical disease evolution.
Full text: Click here
Publication 2023
Animals Biological Evolution Biopharmaceuticals Disease Progression Emulsions Forelimb Freund's Adjuvant Hindlimb IGF1R protein, human Monocytes Mus Mycobacterium tuberculosis Paraparesis Paraplegia Peptides Pertussis Toxin Sterility, Reproductive Tail Tamoxifen
The positional candidate genes were ranked based on their predicted association with seven functional terms related to the Bphs phenotype: Cardiac, G-protein coupled receptor, Histamine, Pertussis toxin, Type I hypersensitivity, Vascular Permeability, and ER/EMC/ERAD. Gene Weaver74 (link) was used to identify genes annotated with each term. Each term was entered the Gene Weaver homepage (https://geneweaver.org) and search restricted to human, rat, and mouse genes, and to curated lists only. Mouse homologs for each gene were retrieved using the batch query tool in MGI (http://www.informatics.jax.org/batch_data.shtml). In addition, using the Gene Expression Omnibus (GEO) and PubMed, additional gene expression data sets were retrieved for each phenotype term. Final gene lists consisted of the unique set of genes associated with each process term.
Full text: Click here
Publication 2023
Benign Prostatic Hyperplasia G-Protein-Coupled Receptors Gene Expression Genes Heart Histamine Homo sapiens Immediate Hypersensitivity Mice, Laboratory Pertussis Toxin Phenotype Vascular Permeability
For induction of EAE, female mice were immunized with 100 μg myelin oligodendrocyte glycoprotein peptide 35–55 (MOG3555, Anawa) in complete Freund's adjuvant supplemented with 5 mg/ml Mycobacterium tuberculosis H37Ra (BD Difco). Two hundred microliters of emulsion was subcutaneously injected into four sites on the flanks of mice. At Days 0 and 2, after initial MOG35‐55 injections, mice received intravenous injection of 100 ng pertussis toxin (Sigma Aldrich). Mice were weighed and scored daily using the following system: 0: no symptom, 1: tail paralysis, 2: hind limb paresis, 2.5: partial hind limb paralysis, 3: Complete hind limb paralysis, 4: forelimb paresis and complete hind paralysis, 5: moribund or dead. Clinical scores were assessed by a blinded investigator.
For tamoxifen injections, mice between 8 and 10 weeks were injected intraperitoneally with tamoxifen in Koliphor (Sigma Aldrich) twice a day with a total of 2 mg/mice/day for 4 consecutive days. Two weeks of washout period were performed before EAE induction.
The Combo protocol was performed as described by Boivin et al (2020 (link)). Briefly, 25 μg of Anti‐Ly6G (clone 1A8, Bio X cell) antibody or isotype control (Rat IgG2a, Bio X cell) were injected intraperitoneally every day for 10 consecutive days, starting from the first symptoms of EAE. Every other day, mice were injected intraperitoneally with 50 μg of anti‐rat Kappa immunoglobulin (Clone MAR 18.5 Bio X cell) or Isotype control.
Full text: Click here
Publication 2023
Cells Clone Cells Emulsions Females Freund's Adjuvant Hindlimb IgG2A Immunoglobulin Isotypes Immunoglobulin kappa-Chains Immunoglobulins Mus Mycobacterium tuberculosis Oligodendrocyte-Myelin Glycoprotein Paraparesis Paresis Peptides Pertussis Toxin Tail Tamoxifen Upper Extremity Paresis
U73122 (S8011, Selleck Chemicals, Houston, TX, USA) is dissolved in dimethyl sulfoxide (DMSO, D8371, Beijing, China), with the final concentration of 9 mM, and stored at −20 °C. For subsequent experiments, combined with cell viability results (see Supplementary data: Supplementary Fig s9a) and previous research results49 (link),54 (link), we selected 9 μM U73122 treatment of HEK for 15 min.
MK-2206 (2HCl) (S1078, Houston, TX, USA) is dissolved in dimethyl sulfoxide (DMSO, D8371, Beijing, China), with the final concentration of 12 mM, and stored at −80 °C. For subsequent experiments, combined with cell viability results (see Supplementary data: Supplementary Fig s9a) and previous research results55 (link), we selected 12 μM MK-2206 treatment of HEK for 24 h.
Pertussis toxin (PTX, P7208, Sigma-Aldrich St., Louis, USA) is dissolved in ddH2O, with the final concentration of 200 μg/ml, and stored at 4 °C. For subsequent experiments, combined with cell viability results (see Supplementary data: Supplementary Fig s9a) and previous research results48 (link), we selected 200 ng PTX treatment of HEK for 4 h.
Fluo-3 AM (F1241, Invitrogen, Thermo Fisher Scientific, USA) is dissolved in dimethyl sulfoxide (DMSO, D8371, Beijing, China), with the final concentration of 3 mM and stored at the light-free conditions at −20 °C.
Full text: Click here
Publication 2023
Cell Survival Fluo-3 Light MK 2206 Pertussis Toxin Sulfoxide, Dimethyl U 73122

Top products related to «Pertussis Toxin»

Sourced in United States, Canada, United Kingdom
Pertussis toxin is a protein produced by the bacterium Bordetella pertussis, the causative agent of whooping cough. It is a key virulence factor and plays a crucial role in the pathogenesis of the disease. The toxin has multiple enzymatic activities and can modulate various cellular processes.
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, Italy, Japan, Poland, Denmark
Pertussis toxin is a bacterial protein produced by the Bordetella pertussis bacterium. It is used in laboratory settings for research purposes.
Sourced in United States, Germany, Canada, China, United Kingdom
Mycobacterium tuberculosis H37Ra is a non-virulent strain of the Mycobacterium tuberculosis bacteria. It is commonly used in research and laboratory settings as a model organism for studying the characteristics and behavior of the Mycobacterium tuberculosis species.
Sourced in United States, China, Germany, United Kingdom, India, France, Japan, Poland, Sao Tome and Principe, Australia, Macao, Canada, Spain, Denmark, Israel, Sweden
Complete Freund's adjuvant is a laboratory reagent used to enhance the immune response in laboratory animals during the production of antibodies. It contains inactivated and dried mycobacteria suspended in a mineral oil emulsion. The mycobacteria component serves to stimulate the animal's immune system, leading to a stronger and more sustained antibody response to the antigen of interest.
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, China, Macao, Italy, France, Switzerland, Canada
The CFA is a laboratory equipment that performs chemical analyses. It is designed to automate and streamline the process of analyzing chemical samples. The CFA can perform a variety of tests and measurements, such as concentration determination, pH analysis, and spectrophotometric analyses. The device is intended for use in research, industrial, and clinical laboratory settings.
Sourced in United States, United Kingdom, Belgium, Germany, Sao Tome and Principe
Pertussis toxin (PTX) is a multi-subunit protein produced by the bacterium Bordetella pertussis, the causative agent of whooping cough. It is a key component in the acellular pertussis vaccine and is used in various laboratory research applications.
Sourced in United States, Denmark, Italy, Germany
Bordetella pertussis toxin is a purified protein derived from the bacterium Bordetella pertussis. It is a laboratory reagent used for research purposes.
Sourced in United States, China, Germany, United Kingdom, Sao Tome and Principe, Canada, Australia, Spain, France, Italy, Israel, Macao, Senegal, Japan
Incomplete Freund's adjuvant is a laboratory reagent used to enhance the immune response in certain immunological experiments. It is a water-in-oil emulsion that contains mineral oil and mannide monooleate, but does not contain killed or attenuated microorganisms like the complete Freund's adjuvant. The incomplete Freund's adjuvant is used to induce a strong, sustained immune response without the granulomatous reaction associated with the complete formulation.
Sourced in United States, China
Mycobacterium tuberculosis is a slow-growing, acid-fast bacillus that is the causative agent of tuberculosis. It is a critical component in the diagnosis and research of this serious infectious disease.
Sourced in United States, Japan, Germany, Denmark, United Kingdom
Complete Freund's adjuvant is a water-in-oil emulsion containing killed mycobacteria. It is used as an immunological adjuvant to enhance the body's immune response to an antigen.

More about "Pertussis Toxin"

Pertussis toxin (PTX) is a crucial exotoxin produced by the bacterium Bordetella pertussis, the causative agent of the respiratory illness whooping cough.
This multifunctional protein plays a central role in the pathogenesis of pertussis, exhibiting a range of biological activities that contribute to the severity of the disease.
PTX has been extensively studied for its potential applications in vaccine development, as well as its use as a research tool to elucidate cellular signaling pathways.
Optimizing the use of pertussis toxin in your research can be facilitated by PubCompare.ai, a platform that leverages advanced AI to identify the most effective products and methodologies from the available literature, pre-prints, and patents.
This can enhance the reproducibility and accuracy of your pertussis toxin-related studies.
Pertussis toxin is also known as Bordetella pertussis toxin and has been used in combination with other adjuvants like Mycobacterium tuberculosis H37Ra and Complete Freund's adjuvant (CFA) to enhance immune responses in research settings.
The incomplete Freund's adjuvant (IFA) is another commonly used adjuvant that can be used alongside PTX.
By utilizing the insights and capabilities of PubCompare.ai, researchers can streamline their pertussis toxin-related experiments, optimize their protocols, and improve the overall quality and impact of their findings.